[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@andrewcaravello Avatar @andrewcaravello Andrew Caravello, DO

Andrew Caravello, DO posts on X about $ibrx, $nwbo, science, rescue the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence finance XXXX% stocks XXXX% cryptocurrencies XXXX% social networks XXXX% technology brands XXXX%

Social topic influence $ibrx #5, $nwbo #1, science 10.42%, rescue 4.17%, to the 4.17%, future 4.17%, $aim #1, $pfe #46, $mrk #17, $bmy #7

Top accounts mentioned or mentioned by @cfiedle24879045 @maveric92283613 @dcvaxdefender @metacollectiveg @smyley4evr1 @jacobyorkndxt @flemmingbruce @siixandserello @nocontextbrits @ustraderep @commercegov @potuss @drpatsoonshiong @fda @nature @ivanbamartin @andrshidalgo16 @lai9uan @danielacerezo @yale

Top assets mentioned ImmunityBio, Inc. Common Stock (IBRX) Pfizer, Inc. (PFE) Merck & Co., Inc. (MRK) Bristol-Myers Squibb Co (BMY) BIO-TECHNE Corp (TECH) Danaher Corporation (DHR) Polymesh (POLYX)

Top Social Posts

Top posts by engagements in the last XX hours

"🏗 The Gate That Decides: Why $NWBO #DCVax Cannot Risk $FBIO Fate In modern biotech the final courtroom is not in front of a judge but in front of an inspector walking the cleanroom corridors. TLDR On October X 2025 Fortress Biotechs CUTX101 was rejected by the FDA. The therapy had Priority Review strong clinical data and real patient need. But it failed anyway. Why Because the manufacturing plant did not pass inspection. The Complete Response Letter (CRL) was not about the science it was about the factory. This is the hidden truth of modern biotech: the factory is the final trial. No matter"
X Link 2025-10-02T13:58Z 1439 followers, 3986 engagements

"🧬 THE RARE GATE OPENS for $NWBO #DCVax The real world is your placebo. A Narrative on Reform Science and the Quiet Signals Behind the Wall TLDR The MHRA has modernised the United Kingdoms regulatory architecture for rare diseases. The new doctrine directly endorses the evidentiary structures DCVax-L has already generated: external controls real-world comparators digital twin modelling interim survival signals single-authorisation pathways bridging trials with early access and long-term confirmation through NHS data capture. MHRA leadership has also publicly acknowledged that older frameworks"
X Link 2025-11-27T11:08Z 1434 followers, 1745 engagements

"⚠Why Treating #ALC With IL-15 Does Not Cure Cancer And why the $IBRX BioShield thesis collapses in the face of immunology clinical evidence and $NWBO #DCVax biology #Lymphopenia is a recognized diagnosis. It has an ICD code. But treating absolute lymphocyte count (ALC) as if the number itself were the disease fundamentally misinterprets medicine and immunology. Lots of lab abnormalities have ICD-10 codes: Anemia Leukopenia Thrombocytopenia Electrolyte disturbances A diagnostic code does not mean the lab value is the therapeutic target. It simply means the abnormality needs evaluation not"
X Link 2025-11-29T06:46Z 1440 followers, 11.9K engagements

"The NewsNation special is not scientific evidence. It was a sponsored primetime feature centered entirely around Patrick Soon Shiong and multiple outlets have already confirmed that the program was produced in coordination with his company $IBRX. That is why the segment relied on dramatic storytelling emotional interviews and bold claims rather than controlled clinical data. Cuomo is not a scientific reviewer and NewsNation is not a peer reviewed journal. When you strip away the television format every major claim in that segment falls into one of two categories. Either it was a personal"
X Link 2025-11-30T17:30Z 1439 followers, 40.6K engagements

"$IBRX If you are going to challenge scientific accuracy you have to start with the basic facts. $NWBO #DCVax-L excludes only severe lymphopenia for the same reason every T-celldependent immunotherapy does. When there are almost no T cells there is nothing to teach. That is not a contradiction. It is basic immunology. The Phase X glioblastoma trial still included patients with low or moderately low lymphocyte counts and within that population DCVax-L produced a statistically significant survival benefit in both newly diagnosed and recurrent GBM. Median overall survival rose from XXXX to 19.3"
X Link 2025-11-30T18:37Z 1439 followers, 1721 engagements

"$IBRX IL-15 definitely activates NK and CD8 T cells no disagreement there. The issue isnt whether IL-15 activates cells. The issue is whether IL-15 can sustain antitumor immunity long enough to matter in solid tumors. And on that question the evidence is crystal clear: X. Every systemic solid-tumor trial of IL-15 or N-803 has shown the exact same pattern: big NK spikes transient CD8 activation no durable objective responses Wrangle et al. ALT-803 + anti-PD-1 studies QUILT-3.055 in NSCLC all produced immune noise without long-term clinical benefit. X. The only FDA approval is in the bladder"
X Link 2025-12-01T00:47Z 1439 followers, XXX engagements

"Stimulating NK and T cells isnt the question. $IBRX IL-15 is excellent at activation. The problem has always been durability not signal strength. Heres what the evidence shows: X. It works by stimulating NK and T cells is not the same as producing durable tumor control. Every IL-15 trial shows the same pattern: NK spike short CD8 burst no sustained clinical benefit in solid tumors If activation alone cured cancer IL-15 would already be a standard therapy. It isnt for a reason. X. Saying IL-15 helps lymphopenia because its being trialed is not evidence. Actual immune-reconstitution data exist"
X Link 2025-12-01T00:51Z 1439 followers, XXX engagements

"$IBRX The Journal of Urology paper is meaningful for patients with papillary-only NMIBC and no one disputes that bladder preservation is important. But the paper only presents one part of the story and that context matters when discussing FDA policy. The publication covers Cohort B only where #Anktiva was given with BCG intravesically in a very specific localized disease setting. There was no control arm and the outcomes reported in Cohort B are essentially the same outcomes historically seen with BCG alone in papillary disease. If a combination produces the same results as BCG monotherapy"
X Link 2025-12-03T15:54Z 1439 followers, 3167 engagements

"What the data actually show is that $IBRX #Anktiva on its own did not just fail to help. In many cases it produced outcomes worse than what you would expect from BCG alone. That is the central fact everything else has to orbit. If a drug claims to restore or boost immune cells yet performs below the historical baseline of BCG then the biology is not behaving the way the mechanism promises. It is that simple and that fundamental. This mirrors the same clinical principles used across medicine. You do not treat a number. A hemoglobin of X means hemorrhage in trauma renal failure in chronic"
X Link 2025-12-04T10:33Z 1439 followers, 1319 engagements

"@CFiedle24879045 Haha or check out a company thats actually curing cancer. $NWBO #DCVax has peer-reviewed survival data validated across academic centers all over the world"
X Link 2025-12-04T18:03Z 1439 followers, XXX engagements

"That article doesnt reflect where $IBRX actually stands. It skips the central issue that the CIS approval came from a single arm design that never separated the effect of N XXX from a second full induction of BCG which is why the centrally confirmed response rate sits exactly where modern BCG rescue sits. It leaves out that in papillary disease the combination actually performed worse than matched BCG re induction which is why the FDA rejected the sBLA and required a randomized trial. It ignores that newer intravesical options like TAR XXX and CG0070 are now producing higher complete response"
X Link 2025-12-04T18:52Z 1439 followers, XXX engagements

"That #GBM claim for $IBRX is based on a tiny single-arm study using disease control which in #glioblastoma often reflects imaging artifacts rather than drug effect. Nothing in that dataset shows independent activity. If youre looking for an immunotherapy that has actually shifted survival #DCVax-L is the only one with phase X peer-reviewed multi-center evidence across multiple countries. The validated GBM signal in this space belongs to NWBO not IBRX"
X Link 2025-12-04T19:32Z 1439 followers, XXX engagements

"If pointing out the evidence counts as nothing better to do that says more about the bullish case than anything Ive written. The truth is simple: once you separate N-803 from the BCG backbone $IBRX #Anktiva behaves like a placebo. And in papillary disease it was even clearer patients on Anktiva + BCG actually did worse than patients who just received modern BCG re-induction. The recurrence rate was higher the hazard ratio favored BCG alone and thats exactly why the FDA rejected the papillary indication. So if the drug cant show independent benefit in CIS and actually worsens outcomes in"
X Link 2025-12-05T01:19Z 1439 followers, XXX engagements

"You can probably understand why I react the way I do when $IBRX #Anktiva gets framed as some kind of breakthrough. It has failed in every solid tumor setting tested and in bladder cancer it hasnt shown any independent activity beyond what BCG already achieves. In papillary disease the combination actually performed worse than modern BCG re-induction. When you look at it through that lens and when you factor in my own experience watching someone close to me do exactly what the BCG data say many patients can do its not hard to see why this strikes a nerve. Anyone who has been through it with"
X Link 2025-12-05T03:08Z 1439 followers, XXX engagements

"Cant disagree with that 😅 Its a good thing LP chose the UK for first approval. The MHRA has already built the framework for RWE driven tissue agnostic immunotherapies and DCVax fits that model better than anything in big pharmas pipeline. The move protected the science and positions NWBO to come back to the FDA from a position of strength"
X Link 2025-12-05T14:23Z 1436 followers, XX engagements

"This entire claim has no basis in evidence and none of the statements being made about N-803 are supported by clinical data regulatory filings or basic immunology. $IBRX #Anktiva is an IL-15 agonist that expands NK and CD8 cells but immune expansion is not the same as curing cancer clearing viruses fixing antibiotic resistance or extending human lifespan. In every cancer where outcomes can be compared to a known backbone N-803 has failed to show any independent therapeutic effect. In pancreatic cancer it matched third-line chemotherapy. In NSCLC it matched treatment-beyond-progression on"
X Link 2025-12-06T11:07Z 1439 followers, XXX engagements

"THE $NWBO #DCVax HIDDEN ARCHITECTURE Part II of II The Factory The Federation and the Immune Operating System By the time Northwest Biotherapeutics secured commercial rights to the DC1 method the company owned the instructions for the immune system but not yet the factory capable of executing them at scale. Intellectual property can give you the blueprint for a cathedral; it cannot stack a single stone. Manufacturing is the stonework of cell therapy the part of the enterprise that cannot be faked or outsourced indefinitely. NWBO understood this years before the market did. That is why Advent"
X Link 2025-12-06T21:56Z 1440 followers, 1410 engagements

"This argument collapses both scientifically and regulatorily. Epogen and Neupogen are supportive hematologic therapies because they replace or stimulate a specific blood lineage in a predictable way. They do not rely on tumor biology and they do not alter the immune environment outside the targeted lineage. $IBRX #Anktiva does none of this. It is not a lineage support drug. It is an IL fifteen superagonist that pushes NK and T cells into global cytokine activation without correcting the underlying cause of lymphopenia and without any evidence that raising absolute lymphocyte count changes"
X Link 2025-12-07T03:50Z 1439 followers, 1137 engagements

"🔬The Two Cytokines at the Gate: How $IBRX #Anktiva and $NWBO #DCVax Expose the Future Architecture of Cancer Immunity TLDR A 2025 immunology paper on IL-15armored NK and CAR-NK therapies revealed a single phenomenon across every model: early tumor regression followed by uncontrolled immune expansion organ infiltration and premature host death independent of CAR targeting tumor type NK source or dose. IL-15 produces force without structure. IL-7 produces structure without collapse. Clinically $IBRX #Anktiva avoids IL-15s catastrophic biology only by weakening IL-15s potency which is why it"
X Link 2025-12-08T00:45Z 1439 followers, 8011 engagements

"Thats actually pretty rich coming from the side circulating $IBRX #Anktiva claims that arent supported by data. Debunking misinformation is not promotion it is basic medical ethics. Primum non nocere applies just as much to public discussion as it does at the bedside. If someone pushes a narrative that could mislead patients or investors about how a therapy works or what the evidence shows it is not only reasonable to correct it it is responsible. Im not the one telling people that a cytokine booster cures cancer reverses lymphopenia universally or is a platform for all tumors. Im pointing"
X Link 2025-12-08T04:46Z 1439 followers, XXX engagements

"Thank you for bringing this up because the analogy to EPO completely collapses once you understand the difference between treating a mechanism and treating a lab number. When we give EPO it is not because someone proved it extends survival. We give it only in a very specific biologic setting when the kidney fails to produce erythropoietin and red cell production collapses. The same is true in thrombocytopenia and neutropenia. You treat the underlying cause not the number. And even then pushing the number too far can make things worse. The CHOIR trial showed that higher hemoglobin targets"
X Link 2025-12-08T10:46Z 1433 followers, XXX engagements

"🧬 Complete Evidence Map: Kalinskis Science + The $NWBO #DCVax Operating System PART X of X DCVax-T #Eden SI XX And The Strategic Moats Around The Immune Operating System Part X followed the biology from end to end: how CKM hijacks NF kB in tumors how DC1 is manufactured through the GM-CSF and IL X corridor how NK-receptor logic gates emerge how epitope spreading turns a static vaccine into self-updating software and how CXCR3 routing determines whether PD X can work at all. Part X picks up where that leaves off and asks a different question: given this instructional engine how do you"
X Link 2025-12-10T11:46Z 1434 followers, XX engagements

"The Case Against $IBRX #Anktiva: How an IL XX Superagonist Became a Biological Placebo in Value Terms When Anktiva N XXX first appeared on slides and conference stages it sounded like the missing piece of modern oncology. An IL XX superagonist that could awaken exhausted immune cells. Expand natural killer cells and CD8 T cells. Rescue patients whose immune systems had been beaten down by chemo radiation and prior therapies. Plug the energy leak in immunotherapy and turn modest checkpoint responses into durable cures. On paper that is a lovely story. But drugs do not get to live on paper."
X Link 2025-12-04T14:18Z 1440 followers, 3483 engagements

"🧬 The Convergence Architecture: How ImmunityBios $IBRX #Anktiva Is Being Measured Against the #DCVax Instructional Platform at the Center of $NWBO Technology 💡 TLDR The National Cancer Institutes QUILT-502 trial in HER2-positive recurrent or metastatic endometrial cancer is testing four coordinated immune components: a HER2-targeted dendritic-cell vaccine (AdHER2DC) pembrolizumab (Mercks antiPD-1) lenvatinib (Eisais VEGFR/FGFR inhibitor) andonly in one armthe IL-15 superagonist N-803 (Anktiva) from ImmunityBio. QUILT-502 is a Phase I/II study with the Phase II portion designed to evaluate"
X Link 2025-12-08T22:20Z 1440 followers, 4140 engagements

"🧬 Complete Evidence Map: Kalinskis Science + The $NWBO #DCVax Operating System $AIM $PFE $MRK $BMY $TECH $DHR $IBRX $ESALY PART X of X DCVax-T #Eden SI XX And The Strategic Moats Around The Immune Operating System Part X followed the biology from end to end: how CKM hijacks NF kB in tumors how DC1 is manufactured through the GM-CSF and IL X corridor how NK-receptor logic gates emerge how epitope spreading turns a static vaccine into self-updating software and how CXCR3 routing determines whether PD X can work at all. Part X picks up where that leaves off and asks a different question: given"
X Link 2025-12-10T11:48Z 1440 followers, XXX engagements

"🧬 Complete Evidence Map: Kalinskis Science + The $NWBO #DCVax Operating System $AIM $PFE $MRK $BMY $TECH $DHR $IBRX $ESALY PART X OF X TLDR CKM = Chemokine-Modulatory Regimen: Rintatolimod (Ampligen) + Interferon- + a COX-2 inhibitor (usually celecoxib). This three-part regimen selectively boosts CXCL9/10 in NF-Bhigh tumor tissue while avoiding activation in healthy tissue creating a tumor-specific immune switch that turns cold tumors hot. X. CKM is a tumor-selective immune amplifier not a blunt stimulant. In early TNBC (NCT04081389) CKM + paclitaxel produced large CD8 influx high CXCL9/10"
X Link 2025-12-10T11:50Z 1441 followers, 3723 engagements

"🧬 #FDA Just Revealed the Exact Pathway $NWBO #DCVax-L Needs The new FDA Grand Rounds isnt about DCVax but it is about the regulatory engine DCVax-L runs on. On December XX the Agency is dedicating an entire session to Real-World Evidence (RWE)how to validate it how to judge external controls and how to use it in oncology approvals when traditional RCTs are impossible. That matters because DCVax-Ls Phase X trial used: an external control arm a crossover-contaminated dataset and survival outcomes proven through RWE-strength comparisons The invited speaker Dr. Marie Bradley is the FDAs senior"
X Link 2025-12-03T00:34Z 1441 followers, 9748 engagements

"🧱 Tokenizing Trust: Why $NWBO Should Build On Polymesh for Investor Protection Market Integrity IP Security and Long-Term Capital Access TLDR Tokenization is no longer a fringe idea or a crypto experiment. It is becoming a mainstream modernization of traditional market infrastructure but only when executed within the full regulatory framework that governs U S securities. SIFMA the primary policy voice of broker-dealers investment banks custodians and clearing firms has stated openly that tokenized markets must operate with the same investor protections surveillance transparency and lifecycle"
X Link 2025-12-11T00:06Z 1441 followers, 1273 engagements

"📘 VOLUME I THE ARCHITECTURE OF $NWBO #DCVax IMMUNITY Part Two of Two Dendritic Cell Therapies and Modulation of Endogenous DC to Overcome I O via @YouTube How the Antigen Constellation Boolean Logic In Situ Vaccination and CKM Close the Loop of the Immune Operating System SECTION X The Antigen Constellation If the Chemokine Compass determines where immune cells go the Antigen Constellation determines what they see when they arrive. Here Kalinski exposes the core flaw in most targeted immunotherapies for solid tumors. Tumors do not present a single antigen. They present shifting"
X Link 2025-12-11T00:30Z 1441 followers, 1953 engagements